Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination

Patients with extranodal natural killer/T-cell lymphoma (ENKTL), nasal type are benefit from peg-asparaginase, gemcitabine, and methotrexate. Therefore, we conducted a prospective phase II trial using a combination of these drugs as GAD-M regimen in naïve ENKTL patients, simultaneously, explored the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Wang, Cai-Qin, Sun, Peng, Liu, Pan-Pan, Yang, Hang, Wang, Han-Yu, Rao, Hui-Lan, Li, Su, Jiang, Wen-Qi, Huang, Jia-Jia, Li, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818987/
https://www.ncbi.nlm.nih.gov/pubmed/35141162
http://dx.doi.org/10.3389/fonc.2022.796738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818987/
https://www.ncbi.nlm.nih.gov/pubmed/35141162
http://dx.doi.org/10.3389/fonc.2022.796738

Ejemplares similares